| |
RFS
|
CSS
|
|---|
|
Characteristics
|
HR
|
95% CI
|
P
|
HR
|
95% CI
|
P
|
|---|
|
PgR expression
|
|
≥ 20%
|
Referent
|
|
< 20%
|
2.33
|
1.19–4.54
|
0.013
|
5.15
|
2.06–12.85
|
0.00045
|
|
Ki67 labeling index
|
|
≤ 10%
|
Referent
|
|
> 10 and <30%
|
0.52
|
0.18–1.53
|
0.24
|
0.28
|
0.05–1.44
|
0.13
|
|
≥ 30%
|
0.69
|
0.33–1.47
|
0.34
|
0.68
|
0.29–1.57
|
0.36
|
|
Menopausal status
|
|
Pre-
|
Referent
|
|
Post-
|
1.24
|
0.63–2.43
|
0.53
|
0.72
|
0.33–1.61
|
0.43
|
|
Pathological T stage
|
|
T 1–2
|
Referent
|
|
T 3–4
|
1.49
|
0.68–3.25
|
0.32
|
1.51
|
0.58–3.90
|
0.40
|
|
Pathological N stage
|
|
N 0
|
Referent
|
|
N 1–3
|
3.16
|
1.51–6.58
|
0.0022
|
2.69
|
1.04–6.99
|
0.042
|
|
Histological grade
|
|
1,2
|
Referent
|
|
3
|
1.31
|
0.67–2.56
|
0.43
|
1.40
|
0.60–3.25
|
0.44
|
|
Adjuvant chemotherapy
|
|
No
|
Referent
|
|
Yes
|
1.37
|
0.71–2.64
|
0.35
|
1.25
|
0.55–2.82
|
0.59
|
|
Adjuvant endocrine therapy
|
|
No
|
Referent
|
|
Yes
|
1.15
|
0.39–3.37
|
0.80
|
1.20
|
0.27–5.42
|
0.81
|
- Abbreviations: RFS recurrence-free survival, CSS cancer-specific survival, HR hazard ratio, 95% Cl 95% Confidence interval, PgR progesterone receptor
